Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD25 Antibody for GVHD Prophylaxis in Haplo-HSCT with Low-dose ATG
NCT06334367Phase 2Not yet recruiting
- Start
- Mar 2024
- Primary completion
- Mar 2026
- Countries
- 1
01
Overview
Phase 2, randomised trial in graft-versus-host disease (GVHD) (2 arms). Primary endpoints: The incidence of acute Graft-versus-host Disease at 100 days and The incidence of chronic Graft-versus-host Disease at 1 year. Planned start Mar 2024; status: not yet recruiting.
02
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06334367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06334367.